A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
A phase 3 trial testing KC1036 in oesophageal cancer, now recruiting.
Overview
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Oesophageal Cancer is a phase 3 interventional study registered as NCT06194734, led by Beijing Konruns Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Randomised, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of KC1036 Versus Investigator's Choice of Chemotherapy as Third-line Therapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma. Planned enrolment is 490 participants (estimated). The study started in 2024-02-05 and primary completion is expected in 2026-12-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialStudy of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Shares Oesophageal cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Oesophageal cancer and the tag ctgov-ingest.
- TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentLerotinib
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentTQB6411
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentAZD5863
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentHMBD-001
Shares Oesophageal cancer and the tag ctgov-ingest.
- TreatmentHLX43
Shares Oesophageal cancer and the tag ctgov-ingest.